# Benefit of omidenepag isopropyl ophthalmic solution in treatment persistence in Japanese patients with glaucoma

## TL;DR

Omidenepag isopropyl ophthalmic solution showed better treatment persistence in Japanese glaucoma patients compared to other common treatments over three years.

## Contribution

This study demonstrates that omidenepag isopropyl has higher treatment persistence than other glaucoma therapies in a real-world setting.

## Key findings

- The cumulative treatment persistence rate at three years was 27.0% for omidenepag isopropyl versus 20.9% for prostaglandin F receptor agonists.
- The median treatment persistence duration was 281 days for omidenepag isopropyl, longer than 204 days for prostaglandin F receptor agonists and 152 days for beta-blockers.
- Omidenepag isopropyl showed significantly better treatment persistence in a multivariate Cox proportional hazards model.

## Abstract

We conducted a retrospective observational cohort study using a nationwide claims database (JMDC database) to investigate the treatment persistence of antiglaucoma ophthalmic solution monotherapy. Patients aged 18 years or older who were diagnosed with glaucoma between November 2018 and August 2020, and prescribed omidenepag isopropyl (OMDI), prostaglandin F receptor agonists (FP), or beta-blockers (BB) monotherapies were included. A total of 36,450 patients (5,865 patients prescribed OMDI, 20,715 patients prescribed FP, and 9,870 patients prescribed BB) were analyzed. The cumulative treatment persistence rate at three years was 27.0% (95% confidence interval [CI]: 25.9–28.1) in patients prescribed OMDI, which was significantly higher than 20.9% (95% CI: 20.4–21.5) in those prescribed FP; the hazard ratio was 0.835 (95% CI: 0.806–0.865, p < 0.0001), calculated with the multivariate Cox proportional hazards model. The median duration of treatment persistence, calculated with the Kaplan-Meier methods, was 281 days in those prescribed OMDI, 204 days in those prescribed FP, and 152 days in those prescribed BB; the treatment persistence of OMDI tended to be longer than FP or BB. OMDI had a longer treatment persistence compared to other antiglaucoma ophthalmic solutions in the real-world setting, suggesting that OMDI would be a promising first-line treatment option in the long-term management of glaucoma.

The online version contains supplementary material available at 10.1038/s41598-025-22758-w.